PRFX חוב כולל להון PainReform Corp

PainReform Ltd. (PRFX) is currently actively developing PRF-110, a drug aimed at reducing opioid load in postoperative pain management. The business relies on robust patent protection and a unique method for reducing dependence on narcotic substances. Market price visualization on GURU.Markets shows that the debt-to-equity ratio is 0.00, while the firm's success depends on regulatory approval and the adoption of the technology by surgeons.

This indicator measures the proportion of borrowed funds relative to equity, allowing investors to assess the degree of debt load and the business's financial autonomy. By analyzing the debt-to-equity ratio, one can understand how the strategy of PainReform Ltd. (PRFX) to delegate production and logistics to third-party partners reduces the need for capital expenditures and impacts the company's overall credit dependence.